Welcome to YLOAN.COM
yloan.com » Marketing » Aarkstore Enterprise---diabetes Market Forecast To 2013
Marketing Advertising Branding Careers-Employment Change-Management Customer Service Entrepreneurialism Ethics Marketing-Direct Negotiation Outsourcing PR Presentation Resumes-Cover-Letters Sales Sales-Management Sales-Teleselling Sales-Training Strategic-Planning Team-Building Top7-or-Top10-Tips Workplace-Communication aarkstore corporate advantages development collection global purchasing rapidshare grinding wildfire shipping trading economy wholesale agency florida attorney strategy county consumer bills niche elliptical

Aarkstore Enterprise---diabetes Market Forecast To 2013

Which companies are poised to dominate the diabetes market

? With new classes on the rise, which innovative therapies will make an impact? How will clinical results and safety issues affect drug profitability over the long term?

A veteran analysts answer these questions and more by placing critical drug information in a relevant industry-wide context. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers all in one, easy-to-read format.

From showing the most accurate sales projections and pipelines to identifying market threats and opportunities, Diabetes Market Forecast to 2013 provides teams with a hard-hitting, penetrating analysis of the global diabetes market. For reliable evidence to support key resource allocation decisions, this is the only resource youll need.

Give your brand team all the diabetes data it needs to make critical product decisions!


Table of Contents :

Type I Antidiabetic Treatments

Traditional Insulins

Novolin

Humulin

Short-Acting Insulin Analogs

Novolog

Humalog

Apidra

Long-Acting Insulin Analogs

Levemir

Lantus

Other Drugs

Symlin

Technosphere

Teplizumab

Otelixuzumab

TT-223

Type II Antidiabetic Treatments

DPP-4 Inhibitors

Januvia (includes Janumet)

Galvus (includes Eucreas)

Alogliptin

Onglyza

GLP-1 Analogs

Byetta (includes Byetta Long-Acting Release)

Liraglutide

AVE0010

Syncria

Tapsoglutide

SGLT-2 Inhibitors

AVE2268

Remogliflozin

Dapagliflozin

Sulfonylureas

Amaryl

Glucotrol

For more information please contact :

http://www.aarkstore.com/reports/Diabetes-Market-Forecast-to-2013-6771.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise
Aarkstore Enterprise---oncology Market Forecast To 2013 Zenith Grinding Mill Process Fly Ash Wide Market Prospect Ways to Make Investment in the Stock Markets How To Have A Successful Affiliate Marketing Program Aarkstore Enterprise---pharmaceutical Product Relaunch: Preserving Market Share Through Line Extensi Aarkstore Enterprise---early-stage Pharmaceutical Marketing Budgets: Preparing For Product Launch Aarkstore Enterprise---post-launch Brand Marketing In Select Affiliate Markets How to Launch an Email Marketing Campaign Consumer Mailing Lists A Significant Necessity For E Marketing The Perils Of Viral Video Marketing The Five Effective Avenues Of Marketing Your Website Observation: Domestic Appliances Corps Mobile Swallow Small Profit Can The Small Investor Surive In This Market?
print
www.yloan.com guest:  register | login | search IP(216.73.216.60) California / Anaheim Processed in 0.017718 second(s), 7 queries , Gzip enabled , discuz 5.5 through PHP 8.3.9 , debug code: 96 , 2301, 66,
Aarkstore Enterprise---diabetes Market Forecast To 2013 Anaheim